What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight.

In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities." This new guidance will clearly impact the clinical research field, but how?

In this exclusive webinar, Dr. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.

Learning Objectives:

Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development?
Explore the limitations of what we know about prescription drug dosing
The future of Clinical Research

April 12, 2023 at 11:00 am PDT, 2:00 pm EDT, 7:00 pm GMT

Brought to you by:

Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

Ben Locwin is a biopharmaceutical executive. For over two decades, he has worked on the development and commercialization of drug therapies. He has worked in designing and conducting clinical trials and has been a part of many healthcare task forces. He has also been featured in dozens of industry publications, as well as The Wall Street Journal, USA Today, Forbes, Der Spiegel, The Associated Press, and other top-tier media.

Pharma Rep Focus